高级搜索

107例鼻型NK/T细胞淋巴瘤临床特点和预后分析

陈道光, 杨瑜, 陈刚, 吴君心, 肖景榕, 吴晖, 何鸿鸣, 陈英, 林剑扬, 邹思平

陈道光, 杨瑜, 陈刚, 吴君心, 肖景榕, 吴晖, 何鸿鸣, 陈英, 林剑扬, 邹思平. 107例鼻型NK/T细胞淋巴瘤临床特点和预后分析[J]. 肿瘤防治研究, 2013, 40(09): 873-876. DOI: 10.3971/j.issn.1000-8578.2013.09.013
引用本文: 陈道光, 杨瑜, 陈刚, 吴君心, 肖景榕, 吴晖, 何鸿鸣, 陈英, 林剑扬, 邹思平. 107例鼻型NK/T细胞淋巴瘤临床特点和预后分析[J]. 肿瘤防治研究, 2013, 40(09): 873-876. DOI: 10.3971/j.issn.1000-8578.2013.09.013
shu
CHEN Daoguang, YANG Yu, CHEN Gang, WU Junxin, XIAO Jingrong, WU Hui, HE Hongming, CHEN Ying, LIN Jianyang, ZOU Siping. Clinical Characteristics and Prognostic Analysis of 107 Cases of Nasal NK/T-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 873-876. DOI: 10.3971/j.issn.1000-8578.2013.09.013
Citation: CHEN Daoguang, YANG Yu, CHEN Gang, WU Junxin, XIAO Jingrong, WU Hui, HE Hongming, CHEN Ying, LIN Jianyang, ZOU Siping. Clinical Characteristics and Prognostic Analysis of 107 Cases of Nasal NK/T-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 873-876. DOI: 10.3971/j.issn.1000-8578.2013.09.013
shu

107例鼻型NK/T细胞淋巴瘤临床特点和预后分析

  • 1.350014 福州，福建医科大学教学医院福建省肿瘤医院淋巴瘤内科，2.病理科，3.放射治疗科， 4.流行病研究室

详细信息
    作者简介:

    陈道光（1970-），男，硕士，副主任医师，主要从事恶性淋巴瘤研究

    通讯作者:

    杨瑜，E-mail: yangyu901@163.com

  • 中图分类号: R733.4

Clinical Characteristics and Prognostic Analysis of 107 Cases of Nasal NK/T-cell Lymphoma

  • 1.Department of Lymphoma,Fujian Provincial Tumor Hospital,Fujian Medical University,Fuzhou 350014,China,2.Department of Pathology,3.Department of Radiotherapy,4.Department of Epidemiology

摘要

    摘要
  • 摘要: 目的 分析107例鼻型NK/T细胞淋巴瘤的临床特点，探讨影响预后的因素。 方法 回顾性分析2002年1月—2010年12月间福建省肿瘤医院收治的107例完整资料的鼻型NK/T细胞淋巴瘤患者，将临床特点及实验室检查结果进行单因素分析，单因素分析有统计学意义的指标纳入多因素分析。 结果 107例患者男女比例为2.2∶1(74[DK]∶33)，年龄9～83岁，中位年龄42岁。原发部位：鼻腔75例（70％）、韦氏环24例（22％）、其他部位8例；伴颈部淋巴结受侵12例（11％）、骨髓侵犯2例；82％为Ann Arbor分期Ⅰ/Ⅱ期；83%国际预后指数评分为0～1分， 52％伴有B症状。单纯化疗26例、单纯放疗26例、化放疗综合治疗55例。 初治完全缓解率61％，5年生存率47.2%，多因素分析显示年龄、分期、近期疗效是NK/T细胞淋巴瘤的独立预后因素。 结论 鼻型NK/T细胞淋巴瘤主要侵犯鼻腔和韦氏环，男性多见，常伴B症状，放化疗为其主要治疗手段，年龄、分期、近期疗效可作为预后参考因素。

     

    Abstract: Objective To retrospectively analyze the clinical characteristics and long-term treatment outcome of 107 cases of extranodal NK/T-cell lymphoma of nasal type (ENKTL) and investigate the prognostic factors. Methods One hundred and seven cases of patients with pathologically confirmed ENKTL who were admitted to Fujian Provincial Tumor Hospital from January 2002 to December 2010 were analyzed. Univariate analysis was firstly applied for each clinical and laboratory characteristic. The statistically significant factors were then included in multivariate analysis. Results In 107 patients, 74 were male and 33 were female (M[DK]∶F=2.2∶1), with median age of 42 years (range, 9 to 83 years). The most common sites of involvement were nasal cavity (75 cases, 70%), followed by Waldeyer's ring (24 cases, 22%) and others (8 cases). Twelve cases (11%) involved in cervical lymph nodes and only 2 patients had bone marrow metastasis. According to the Ann Arbor staging system, 82% patients were staged as Ⅰ/Ⅱ, 83% had international prognostic index (IPI) of 0~1, and 52% presented with B symptoms. Twenty six patients received chemotherapy alone, 26 patients received radiotherapy alone, and the other 55 patients received radiochemotherapy. The complete response rate for all patients was 61% and the five-year survival rate was 47.2%. Multivariate Cox regression model analysis showed that age, stage and complete remission were all independent prognostic factors of NK/T cells lymphadenoma. Conclusion ENKTL is more often seen in male patients accompanied by B symptoms. Nasal cavity and Waldeyer's ring are the most common primary sites. Radiotherapy and chemotherapy are the main treatment. Age, stage and complete remission to primary treatment are independent prognostic factors.

     

    • HTML全文
    • 参考文献(19)
  • [1] Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy[J]. Cancer,1998,83(3):449-56.
    [2] Lin ZX, Gao Y, Huang HQ, et al. Long-term outcomes of patients with newly diagnosed NK/T-cell lymphoma treated by EPOCH regimen[J].Zhongshan Da Xue Xue Bao(Yi Xue Ke Xue Ban),2010,31(2):274-7.[林泽晓,高岩,黄慧强,等.EPOCH方案一线治疗NK/T细胞淋巴瘤的长期随访结果报告[J].中山大学学报（医学科学版）,2010,31(2):274-7.]
    [3] Fang Y, Yang JM, Song XM, et al. Clinical study of 44 patients with extranodal NK/T-cell lymphoma，nasal type [J].Zhongguo Lin Chuang Yi Shi Za Zhi(Dian Zi Ban),2010,4(5):583-90.[方圆,杨建明,宋献明,等.结外鼻型NK/T细胞淋巴瘤临床分析[J].中国临床医师杂志(电子版),2010,4(5):583-90.]
    [4] Li L, Liu YH, Zhuang HG,et al. Extranodal nasal type NK/T-cell lymphoma：clinicopathologic and prognostic study of 55 cases[J].Zhonghua Bing Li Xue Za Zhi,2009,38(4):237-42.[李丽,刘艳辉,庄恒国,等.结外鼻型NK/T细胞淋巴瘤的临床病理特征及预后分析[J].中华病理学杂志,2009,38(4):237-42.]
    [5] Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project[J].Blood, 2009,113(17):3931-7.
    [6] Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study[J]. J Clin 0ncol,2006,24(4):612-8．
    [7] Yao B, Li YX, Fang H, et al.Prognostic factors and treatment outcome in early stage nasal NK/T cell lymphoma[J].Zhonghua Xue Ye Xue Za Zhi,2006,27(4):222-5.[姚波,李晔雄,房辉,等.116例早期鼻腔NK/T细胞淋巴瘤患者的治疗结果和预后因素分析[J].中华血液学杂志,2006,27(4):222-5.]
    [8] Ma HH, Zhang HY, Qian LT, et al. Prognostic factors and long term treatment outcome of 71 cases of nasal NK/T cell lymphoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2008,17(1):7-10.[马辉辉,张红雁,钱立庭,等.71例鼻腔NK/T细胞淋巴瘤放化疗效和预后因素分析[J].中华放射肿瘤学杂志,2008,17(1):7-10.]
    [9] Ruan HG, Wu M.The clinical treatment and prognostic factors of 60 nasal NK/T cell lymphoma patients[J].Shi Yong Ai Zheng Za Zhi,2009,24(3):291-3.[阮寒光,邬蒙.鼻腔NK/T细胞淋巴瘤60例临床治疗和预后分析[J].实用癌症杂志,2009,24(3):291-3.]
    [10] Thieblemont C, Coiffier B. Lymphoma in older patients[J].J Clin Oncol, 2007,25(4): 1916-23.
    [11] Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL) [J].Clin Lymphoma,2001,1(4): 278-84.
    [12] Wang ZY, Li YX,Wang H, et al. Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma[J].Ann Oncol,2011,22(2):390-6.
    [13] Oshimi K. Progress in understanding and managing natural killer-cell malignancies[J].Br J Haematol,2007,139(4):532-44.
    [14] Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type[J].Clinl Oncol(R Coll Radiol),2008,20(8):619-25.
    [15] Ma HH, Qian LT, Pan HF, et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma[J].Med Oncol,2010,27(3):798-806.
    [16] Pan ZH,Huang HQ,Lin XB,et al.Prognostic analysis of patents with Nasal-Type NK/T Non-Hodgkin's lymphoma―a report of 93 cases [J].Ai Zheng,2005,24(12):1493-7. [潘战和,黄慧强,林旭滨,等.鼻型NK/T细胞非霍奇金淋巴瘤预后因素探讨(附93例长期随访结果分析)[J].癌症,2005,24(12):1493-7.]
    [17] Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia[J].Cancer Sci,2008,99(5): 1016-20.
    [18] Jaccard A, Gachard N, Marin B,et al. Efficacy of L-asparaginase with methotrexate and dexamethasone(AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study[J].Blood,2011,117(6): 1834-9.
    [19] Yamaguchi M, Tobinai K, Oguchi M,et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211[J].J Clin Oncol,2009, 27(33):5594-600.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1733
  • HTML全文浏览量:  18
  • PDF下载量:  365
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-27
  • 修回日期:  2012-10-28
  • 刊出日期:  2013-09-24

目录

摘要
HTML全文
    参考文献(19)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：12192337 今日访问：15379

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭